ZHAOKE OPHTH-B(06622): The phase II study of Carbocisteine bromide and memantine eye drops (YUVEZZI) in Chinese presbyopia patients met the primary endpoint.

ZHAOKE OPHTH-B (06622) announced that the company's innovative drug, BrimocholPF (carbachol tartrate bromonidine eye drops) (YUVEZZI), has met the pre-defined primary endpoint in a Phase II clinical study conducted in China. The therapy has shown good tolerance and favorable safety characteristics. The company plans to further discuss with the Center for Drug Evaluation of the National Medical Products Administration to advance to Phase III clinical trials. It is reported that the Phase II clinical study of BrimocholPF (carbachol tartrate bromonidine eye drops) in China was a multicenter, randomized, double-blind, crossover, placebo-controlled trial designed to evaluate the efficacy and safety of BrimocholPF and CarbacholPF (carbachol eye drops) in patients with presbyopia in China. This trial was led by Professor Qu Jia from the Affiliated Eye Hospital of Wenzhou Medical University and conducted at 13 research centers in China, enrolling a total of 119 subjects. The primary endpoint was the proportion of subjects who, at specified assessment time points, had an improvement of 15 letters in monocular corrected near visual acuity (MCNVA) in the treated eye compared to baseline while maintaining monocular corrected distance visual acuity (MCDVA); maintaining monocular corrected distance visual acuity was defined as a decline of no more than 5 letters compared to baseline.